Hematology TimesResearch explains why cisplatin causes hearing lossDecember 28, 2017Lymphoma & Plasma Cell DisordersMultiple MyelomaHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
Hematology NewsSurvival improvements lag for young Hispanic patients with myelomaDecember 27, 2017Multiple MyelomaLymphoma & Plasma Cell Disorders
Hematology TimesDrug receives fast track, orphan designations for PTCLDecember 27, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Hematology NewsSingle-agent daratumumab active in smoldering multiple myelomaDecember 26, 2017Multiple MyelomaLymphoma & Plasma Cell Disorders
Hematology NewsStudy identifies predictors of acquired von Willebrand diseaseDecember 26, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersBleeding Disorders
Hematology TimesChemo-free combo should be option for rel/ref CLL, doc saysDecember 22, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesRisk stratification may be possible with JCAR017December 21, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesPembrolizumab sBLA receives priority reviewDecember 16, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesPrimary analysis confirms interim findings of CTL019 in DLBCLDecember 15, 2017Lymphoma & Plasma Cell DisordersAggressive LymphomasFollicular Lymphoma
Hematology TimesProviders endorse medical marijuana for kids with cancerDecember 15, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatrics
Hematology NewsVIDEO - New lymphoma drug approvals: Clinical use, future directionsDecember 14, 2017Mantle Cell LymphomaAggressive LymphomasLymphoma & Plasma Cell DisordersImmuno-oncologyFollicular Lymphoma
Hematology TimesA+AVD improves modified PFS in advanced HLDecember 14, 2017Lymphoma & Plasma Cell DisordersHodgkin Lymphoma
Hematology TimesTechnique may be effective for diagnosing NHLDecember 14, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology NewsVIDEO: Ibrutinib PFS is nearly 3 years in MCL patients who had one prior therapyDecember 13, 2017Mantle Cell LymphomaLymphoma & Plasma Cell DisordersAggressive Lymphomas
Hematology NewsVTE rates in lenalidomide-treated NHL may warrant prophylaxisDecember 12, 2017ThrombosisAggressive LymphomasLymphoma & Plasma Cell Disorders
